Sector ratings Charles River Laboratories International, Inc.

Equities

Real-time Estimate Cboe BZX Other stock markets 16:04:48 11/05/2026 BST			5-day change	1st Jan Change
171.92 ^USD	-3.21%		+0.70%	-13.01%

05-08	Charles River Laboratories International, Inc. Seeks M&A Opportunities	CI
05-07	Tranche Update on Charles River Laboratories International, Inc.'s Equity Buyback Plan announced on November 5, 2025.	CI

Sector:

Location:

X axis:

Main competitors

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Capi.($)	Investor	ESG MSCI	Fundamentals	Financial revisions	Global Valuation	Visibility	Consensus
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	8.56B		AA
LONZA GROUP AG	43.39B		AAA
BEONE MEDICINES AG	34.7B		-
REVOLUTION MEDICINES, INC.	30.15B	-	B	-		-
IQVIA HOLDINGS INC.	29.83B		AAA
CELLTRION, INC.	28.46B		A
ASCENDIS PHARMA A/S	14.82B	-	-	-		-		-
REGENCELL BIOSCIENCE HOLDINGS LIMITED	14.48B	-	-	-	-	-	-	-
IONIS PHARMACEUTICALS, INC.	12.51B	-	A	-		-
EUROFINS SCIENTIFIC SE	12.29B		AA
MEDPACE HOLDINGS, INC.	12.11B		BBB
ABIVAX	9.83B	-	BBB	-		-
ICON PUBLIC LIMITED COMPANY	9.51B		AAA
PRAXIS PRECISION MEDICINES, INC.	9.2B	-	B	-		-
TEMPUS AI, INC.	8.95B		A			-
BLUEPRINT MEDICINES CORPORATION	8.38B	-	BB	-		-	-	-
BACHEM HOLDING AG	7.74B		A
BIO-TECHNE CORPORATION	7.57B		AA
KYMERA THERAPEUTICS, INC.	7.08B	-	BBB	-		-
QIAGEN N.V.	6.83B		AAA
Average	15.82B		A
Weighted average by Cap.			A